New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, they may cause immune-related adverse events. Although there have been a few reports of new-onset type 1 diabetes mellitus (T1DM) during ICI treatment, T1DM as a delayed immune-related event after discontinuing immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Je Hyun, Lim, Taekyu, Ham, Ahrong, Kim, Ye An, Lee, Miji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439731/
https://www.ncbi.nlm.nih.gov/pubmed/36107574
http://dx.doi.org/10.1097/MD.0000000000030456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439731/
https://www.ncbi.nlm.nih.gov/pubmed/36107574
http://dx.doi.org/10.1097/MD.0000000000030456

Ejemplares similares